Evidence map›Paper›PMID 41714137›Full record

ArticleLife science alliance2026

Glycolysis inhibition in tuberculosis-driven metabolic rewiring reduces HIV-1 spread in macrophages.

Zoï Vahlas, Clara Deyts, Steven Fried, Myriam Ben Neji, Maxime Pingret, Natacha Faivre, Sarah C Monard, Quentin Hertel, Mariano Maio, Joaquina Barros and 11 more

Abstract read
In one paragraph

Article in Life science alliance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Zoï VahlasInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.
Clara DeytsInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.
Steven FriedInstitut des Maladies Métaboliques et Cardiovasculaires, Inserm, Toulouse, France.
Myriam Ben NejiInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.
Maxime PingretInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.
Natacha FaivreInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.
Sarah C MonardInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.ORCID 0000-0001-7149-312X
Quentin HertelInstitut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, CNRS UMR9004, Montpellier, France.
Mariano MaioInternational Research Project CNRS "MAC-TB/HIV", Toulouse, France.
Joaquina BarrosInternational Research Project CNRS "MAC-TB/HIV", Toulouse, France.
Alexandre LucasInstitut des Maladies Métaboliques et Cardiovasculaires, Inserm, Toulouse, France.
Thien Phong Vu ManhAix-Marseille University, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Turing Center for Living Systems, Marseille, France.
Marcelo CortiHospital de Infecciosas Dr. F.J. Muñiz, Buenos Aires, Argentina.
Renaud PoinclouxInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.
Fabien BlanchetInstitut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, CNRS UMR9004, Montpellier, France.ORCID 0000-0003-3168-0697
Brigitte Raynaud-MessinaInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.
Fabien LetisseInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.
Olivier NeyrollesInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.
Geanncarlo Lugo-VillarinoInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France Geanncarlo.Lugo@ipbs.fr.ORCID 0000-0003-4620-8491
Luciana BalboaInternational Research Project CNRS "MAC-TB/HIV", Toulouse, France.
Christel VérolletInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France christel.verollet@ipbs.fr.ORCID 0000-0002-1079-9085

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB) is a significant aggravating factor in individuals living with HIV-1, the causative agent for AIDS. Both

Indexed as

GlycolysisHIV-1HIV InfectionsMacrophagesTuberculosisGlucoseHost-Directed TherapyHumansHypoxia-Inducible Factor 1, alpha SubunitMetabolic ReprogrammingMycobacterium tuberculosisGlucoseHIF1A protein, humanHypoxia-Inducible Factor 1, alpha Subunit

Identifiers

PMID41714137
PMCPMC12920055

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.